SCI Pharmtech, Inc. (4119.TW)
TWD 68.2
(-0.15%)
TWD 68.2
(-0.15%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.04 Billion TWD | 91.15% |
| 2022 | 545.37 Million TWD | 25207.61% |
| 2021 | 2.15 Million TWD | -16.73% |
| 2020 | 2.58 Million TWD | -13.5% |
| 2019 | 2.99 Million TWD | 0.0% |
| 2018 | - TWD | 0.0% |
| 2017 | - TWD | -100.0% |
| 2016 | 1.05 Million TWD | -50.61% |
| 2015 | 2.14 Million TWD | -99.66% |
| 2014 | 635.03 Million TWD | -6.31% |
| 2013 | 677.78 Million TWD | 1410.24% |
| 2012 | 44.87 Million TWD | -75.8% |
| 2011 | 185.41 Million TWD | 0.07% |
| 2010 | 185.29 Million TWD | 2837.38% |
| 2009 | 6.3 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.02 Billion TWD | -1.21% |
| 2024 Q2 | 1.12 Billion TWD | 9.58% |
| 2023 Q4 | 1.04 Billion TWD | 18.31% |
| 2023 Q2 | 698.92 Million TWD | -24.67% |
| 2023 Q3 | 881.12 Million TWD | 26.07% |
| 2023 FY | 1.04 Billion TWD | 91.15% |
| 2023 Q1 | 927.79 Million TWD | 70.12% |
| 2022 Q4 | 545.37 Million TWD | 153.33% |
| 2022 Q3 | 215.28 Million TWD | -2.21% |
| 2022 FY | 545.37 Million TWD | 25207.61% |
| 2022 Q2 | 220.14 Million TWD | -37.66% |
| 2022 Q1 | 353.16 Million TWD | 16287.94% |
| 2021 Q2 | 2.97 Million TWD | 46.48% |
| 2021 Q4 | 2.15 Million TWD | -16.02% |
| 2021 FY | 2.15 Million TWD | -16.73% |
| 2021 Q1 | 2.03 Million TWD | -21.52% |
| 2021 Q3 | 2.56 Million TWD | -13.75% |
| 2020 FY | 2.58 Million TWD | -13.5% |
| 2020 Q3 | 3.1 Million TWD | 55.36% |
| 2020 Q4 | 2.58 Million TWD | -16.62% |
| 2020 Q1 | 2.49 Million TWD | -16.58% |
| 2020 Q2 | 1.99 Million TWD | -19.95% |
| 2019 Q1 | 3.64 Million TWD | 0.0% |
| 2019 FY | 2.99 Million TWD | 0.0% |
| 2019 Q4 | 2.99 Million TWD | 10.28% |
| 2019 Q3 | 2.71 Million TWD | -14.71% |
| 2019 Q2 | 3.18 Million TWD | -12.8% |
| 2018 Q2 | - TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 FY | - TWD | 0.0% |
| 2018 Q1 | - TWD | 0.0% |
| 2018 Q3 | - TWD | 0.0% |
| 2017 Q3 | - TWD | -100.0% |
| 2017 FY | - TWD | -100.0% |
| 2017 Q4 | - TWD | 0.0% |
| 2017 Q2 | 13 Thousand TWD | 0.0% |
| 2017 Q1 | - TWD | -100.0% |
| 2016 Q3 | 85 Thousand TWD | -99.58% |
| 2016 Q4 | 1.05 Million TWD | 1144.71% |
| 2016 FY | 1.05 Million TWD | -50.61% |
| 2016 Q1 | 205 Thousand TWD | -90.43% |
| 2016 Q2 | 20.08 Million TWD | 9697.07% |
| 2015 Q4 | 2.14 Million TWD | -50.5% |
| 2015 Q3 | 4.32 Million TWD | -98.81% |
| 2015 Q2 | 364.11 Million TWD | -37.83% |
| 2015 Q1 | 585.63 Million TWD | -7.78% |
| 2015 FY | 2.14 Million TWD | -99.66% |
| 2014 FY | 635.03 Million TWD | -6.31% |
| 2014 Q4 | 635.03 Million TWD | -11.02% |
| 2014 Q3 | 713.68 Million TWD | 1.79% |
| 2014 Q2 | 701.13 Million TWD | 7.73% |
| 2014 Q1 | 650.82 Million TWD | -3.98% |
| 2013 FY | 677.78 Million TWD | 1410.24% |
| 2013 Q1 | 565.43 Million TWD | 1159.91% |
| 2013 Q2 | 582.82 Million TWD | 3.07% |
| 2013 Q3 | 574.2 Million TWD | -1.48% |
| 2013 Q4 | 677.78 Million TWD | 18.04% |
| 2012 Q4 | 44.87 Million TWD | -51.43% |
| 2012 Q2 | 87.74 Million TWD | -21.88% |
| 2012 FY | 44.87 Million TWD | -75.8% |
| 2012 Q1 | 112.32 Million TWD | -39.42% |
| 2012 Q3 | 92.39 Million TWD | 5.3% |
| 2011 Q1 | 128.09 Million TWD | -30.87% |
| 2011 Q2 | 114.46 Million TWD | -10.64% |
| 2011 Q3 | 192.64 Million TWD | 68.31% |
| 2011 Q4 | 185.41 Million TWD | -3.75% |
| 2011 FY | 185.41 Million TWD | 0.07% |
| 2010 FY | 185.29 Million TWD | 2837.38% |
| 2010 Q4 | 185.29 Million TWD | 0.0% |
| 2009 FY | 6.3 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | -440.366% |
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | 3.653% |
| Maywufa Company Ltd. | 442.66 Million TWD | -135.499% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | -67.842% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 91.001% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -39447.572% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | 15.891% |
| PhytoHealth Corporation | 28.11 Million TWD | -3607.893% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | 74.351% |
| PharmaEssentia Corporation | 1.2 Billion TWD | 13.143% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 79.192% |